Yu Li

Ms. Yu Li


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JYJing Yan
Jing Yan
QCQingqing Cai
Qingqing Cai
YLYu Li
Yu Li
YZYi Zhang
Yi Zhang
YZYe Zhao
Ye Zhao
HZHuamin Zhang
Huamin Zhang
Immune checkpoint inhibitors (ICIs) for cancer therapy may induce immune-related adverse events including myocarditis, which occurs infrequently but carries a high mortality rate. Crocins are the active constituents derived from Crocus sativus L. (saffron), and have demonstrated various bioactivities including anti-tumor, anti-inflammation, antioxidation, anti-ischemia, anti-aging, and neuroprotective effects. This study established a subcutaneous xenotransplanted tumor model of human liver cancer in nude mice to better mimic ICI-related myocarditis. Animal experimental results revealed that crocins improved cardiac function, relieved myocardial damage and autoimmune response, and suppressed oxidative stress and inflammatory reaction. Quantitative proteomics and Western blotting verification confirmed that crocins ameliorated experimental ICI-related myocarditis by targeting the Hpx/Nrf2/HO-1 pathway. Molecular docking revealed that the best docking activities were demonstrated by crocin I–HO-1, crocin II–Hpx, and crocin III–Nrf2. These findings shed new light on the development of therapeutic strategies for treating ICI-related myocarditis and provided the fundamental basis for expanding the clinical application of crocins.

Verified
Journal Article
Open access
PDF file
YWYanan Wang
Yanan Wang
JCJunxian Cao
Junxian Cao
YZYingxin Zhou
Yingxin Zhou
XCXuxia Cao
Xuxia Cao
SDShiwen Deng
Shiwen Deng
PCPeng Chen
Peng Chen
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease. Current antifibrotic drugs, exemplified by pirfenidone (PFD), only slow disease progression with limited efficacy and adverse effects, underscoring the need for novel therapeutic strategies. By integrating single-cell transcriptomics with the Drug2Cell algorithm, we performed drug prioritization at single-cell resolution and identified menadione (vitamin K3, VK3), a synthetic naphthoquinone and the minimal core of naturally occurring vitamin K, as a candidate preferentially active in alveolar epithelial cells. In bleomycin (BLM)-stimulated A549 cells and a mouse model of pulmonary fibrosis, therapeutic co-administration of low-dose VK3 and PFD reduced vimentin expression by 44.8% and collagen deposition by 50.3%, and decreased fibroblast abundance by 36.7%, thereby attenuating histopathological damage and restoring BLM-disrupted alveolar epithelial homeostasis. Experiments with VK3 alone further demonstrated that its antifibrotic activity is independent of conversion to vitamin K2. Mechanistically, thermal proteome profiling identified TANK-binding kinase 1 (TBK1) as the principal candidate target; molecular docking and molecular dynamics simulations predicted a stable binding mode, independently confirmed by biolayer interferometry and differential scanning fluorimetry, demonstrating direct binding of VK3 to TBK1 with nanomolar affinity. TBK1 knockdown suppressed BLM-induced fibrotic responses, establishing TBK1 as a positive regulator of pulmonary fibrosis. In vitro signaling analysis revealed that VK3 plus PFD inhibits phosphorylation of TBK1 and STAT3, whereas PFD alone reduces phosphorylation of JAK1 and STAT3, suggesting that both agents converge on STAT3 through distinct upstream nodes. Although VK3 exhibits dose-dependent cytotoxicity precluding direct clinical use as monotherapy, its validated high-affinity target TBK1 and privileged naphthoquinone scaffold lay a rational foundation for lead optimization toward safer anti-IPF agents, and its ability to enhance PFD efficacy supports further development as an adjunct to existing antifibrotic therapy.